Further molecular dissection of how AR modulates the CXCL11/CXCL12/CXCR4/CXCR7 axis to influence the motility of prostate tumor cells is expected to facilitate the development of new hormone-based strategies that are capable of decreasing the metastatic potential of localized prostate cancers exposed to androgens. This evidence concerns the gene AR and prostate neoplasm.